Mediphage signs license option agreement with multinational pharmaceutical company

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Mediphage Bioceuticals (Mediphage), a preclinical-stage company developing safe and redosable non-viral gene therapies based on its proprietary ministring DNATM (msDNATM) technology recently announced that it signed an Evaluation and Option agreement with an undisclosed multinational pharmaceutical company, a leader in the gene therapy space.

Mediphage is an OBIO® member, CAAP® and H2BB™ company, BDSP™ recipient and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Notogen partners with Boehringer Ingelheim to develop a novel regenerative approach to treat degenerative disc disease
Next

AI-enabled scheduling system is improving the patient experience in medical imaging